Q-omics provides the consensus-scored RPL17P3 profile across patient tissues and cancer cell-line models. RPL17P3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPL17P3 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, RPL17P3 RNA expression shows 6,684 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight OV, THCA, and STAD as cancer lineages where RPL17P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL17P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL17P3 survival associations across molecular data types. RPL17P3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL17P3 RNA expression–survival associations across cancer types. High RPL17P3 expression shows unfavorable associations in OV, CHOL, HNSC and ACC, but favorable associations in COAD and LUAD. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for RPL17P3 RNA expression.
This table summarizes RPL17P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL17P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL17P3 shows lower tumor expression in THCA and higher tumor expression in LUAD. The THCA box plot shows higher RPL17P3 RNA expression in normal versus tumor tissue (log2 FC = −0.577, t-test p < 0.001).
This table shows molecular features associated with RPL17P3 in patient tissues and cancer cell lines. In patient samples, RPL17P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
